Exact Mass: 459.2468
Exact Mass Matches: 459.2468
Found 325 metabolites which its exact mass value is equals to given mass value 459.2468
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Cerivastatin
C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AA - Hmg coa reductase inhibitors D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents D004791 - Enzyme Inhibitors > D019161 - Hydroxymethylglutaryl-CoA Reductase Inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor D009676 - Noxae > D000963 - Antimetabolites
Apstatin
SEERZIQQUAZTOL-WOJBJXKFSA-N
Panax ginseng Tetrapeptide
Constituent of Panax ginseng (ginseng). Panax ginseng Tetrapeptide is found in tea.
Trifarotene
D - Dermatologicals > D10 - Anti-acne preparations > D10A - Anti-acne preparations for topical use > D10AD - Retinoids for topical use in acne C274 - Antineoplastic Agent > C2122 - Cell Differentiating Agent > C1934 - Differentiation Inducer C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C804 - Retinoic Acid Agent C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids D003879 - Dermatologic Agents
cyclo(-Phe-Gly-Ala1-Leu-Ala2-)|cyclo(L-alanyl-L-leucyl-L-alanyL-glycyl-L-phenylalanyl)|cyclozanthoxylane A
Asp Val Ala Arg
Ala Ala Ile Trp
Ala Ala Leu Trp
Ala Ala Trp Ile
Ala Ala Trp Leu
Ala Asp Arg Val
Ala Asp Val Arg
Ala Ile Ala Trp
Ala Ile Trp Ala
Ala Lys Asn Gln
Ala Lys Gln Asn
Ala Leu Ala Trp
Ala Leu Trp Ala
Ala Asn Lys Gln
Ala Asn Gln Lys
Ala Gln Lys Asn
Ala Gln Asn Lys
Ala Arg Asp Val
Ala Arg Val Asp
Ala Val Asp Arg
Ala Val Arg Asp
Ala Trp Ala Ile
Ala Trp Ala Leu
Ala Trp Ile Ala
Ala Trp Leu Ala
Cys Ile Lys Pro
Cys Ile Pro Lys
Cys Lys Ile Pro
Cys Lys Leu Pro
Cys Lys Pro Ile
Cys Lys Pro Leu
Cys Leu Lys Pro
Cys Leu Pro Lys
Cys Pro Ile Lys
Cys Pro Lys Ile
Cys Pro Lys Leu
Cys Pro Leu Lys
Asp Ala Arg Val
Asp Ala Val Arg
Asp Gly Ile Arg
Asp Gly Leu Arg
Asp Gly Arg Ile
Asp Gly Arg Leu
Asp Ile Gly Arg
Asp Ile Arg Gly
Asp Leu Gly Arg
Asp Leu Arg Gly
Asp Arg Ala Val
Asp Arg Gly Ile
Asp Arg Gly Leu
Asp Arg Ile Gly
Asp Arg Leu Gly
Asp Arg Val Ala
Asp Val Arg Ala
Glu Gly Arg Val
Glu Gly Val Arg
Glu Arg Gly Val
Glu Arg Val Gly
Glu Val Gly Arg
Glu Val Arg Gly
Gly Asp Ile Arg
Gly Asp Leu Arg
Gly Asp Arg Ile
Gly Asp Arg Leu
Gly Glu Arg Val
Gly Glu Val Arg
Gly Ile Asp Arg
Gly Ile Arg Asp
Gly Lys Gln Gln
Gly Leu Asp Arg
Gly Leu Arg Asp
Gly Gln Lys Gln
Gly Gln Gln Lys
Gly Arg Asp Ile
Gly Arg Asp Leu
Gly Arg Glu Val
Gly Arg Ile Asp
Gly Arg Leu Asp
Gly Arg Val Glu
Gly Val Glu Arg
Gly Val Arg Glu
Gly Val Val Trp
Gly Val Trp Val
Gly Trp Val Val
Ile Ala Ala Trp
Ile Ala Trp Ala
Ile Cys Lys Pro
Ile Cys Pro Lys
Ile Asp Gly Arg
Ile Asp Arg Gly
Ile Gly Asp Arg
Ile Gly Arg Asp
Ile Lys Cys Pro
Ile Lys Pro Cys
Ile Pro Cys Lys
Ile Pro Lys Cys
Ile Arg Asp Gly
Ile Arg Gly Asp
Ile Trp Ala Ala
Lys Ala Asn Gln
Lys Ala Gln Asn
Lys Cys Ile Pro
Lys Cys Leu Pro
Lys Cys Pro Ile
Lys Cys Pro Leu
Lys Gly Gln Gln
Lys Ile Cys Pro
Lys Ile Pro Cys
Lys Leu Cys Pro
Lys Leu Pro Cys
Lys Asn Ala Gln
Lys Asn Gln Ala
Lys Pro Cys Ile
Lys Pro Cys Leu
Lys Pro Ile Cys
Lys Pro Leu Cys
Lys Gln Ala Asn
Lys Gln Gly Gln
Lys Gln Asn Ala
Lys Gln Gln Gly
Leu Ala Ala Trp
Leu Ala Trp Ala
Leu Cys Lys Pro
Leu Cys Pro Lys
Leu Asp Gly Arg
Leu Asp Arg Gly
Leu Gly Asp Arg
Leu Gly Arg Asp
Leu Lys Cys Pro
Leu Lys Pro Cys
Leu Pro Cys Lys
Leu Pro Lys Cys
Leu Arg Asp Gly
Leu Arg Gly Asp
Leu Trp Ala Ala
Asn Ala Lys Gln
Asn Ala Gln Lys
Asn Lys Ala Gln
Asn Lys Gln Ala
Asn Gln Ala Lys
Asn Gln Lys Ala
Pro Cys Ile Lys
Pro Cys Lys Ile
Pro Cys Lys Leu
Pro Cys Leu Lys
Pro Ile Cys Lys
Pro Ile Lys Cys
Pro Lys Cys Ile
Pro Lys Cys Leu
Pro Lys Ile Cys
Pro Lys Leu Cys
Pro Leu Cys Lys
Pro Leu Lys Cys
Pro Arg Ser Thr
Pro Arg Thr Ser
Pro Ser Arg Thr
Pro Ser Thr Arg
Pro Thr Arg Ser
Pro Thr Ser Arg
Gln Ala Lys Asn
Gln Ala Asn Lys
Gln Gly Lys Gln
Gln Gly Gln Lys
Gln Lys Ala Asn
Gln Lys Gly Gln
Gln Lys Asn Ala
Gln Lys Gln Gly
Gln Asn Ala Lys
Gln Asn Lys Ala
Gln Gln Gly Lys
Gln Gln Lys Gly
Arg Ala Asp Val
Arg Ala Val Asp
Arg Asp Ala Val
Arg Asp Gly Ile
Arg Asp Gly Leu
Arg Asp Ile Gly
Arg Asp Leu Gly
Arg Asp Val Ala
Arg Glu Gly Val
Arg Glu Val Gly
Arg Gly Asp Ile
Arg Gly Asp Leu
Arg Gly Glu Val
Arg Gly Ile Asp
Arg Gly Leu Asp
Arg Gly Val Glu
Arg Ile Asp Gly
Arg Ile Gly Asp
Arg Leu Asp Gly
Arg Leu Gly Asp
Arg Pro Ser Thr
Arg Pro Thr Ser
Arg Ser Pro Thr
Arg Ser Thr Pro
Arg Thr Pro Ser
Arg Thr Ser Pro
Arg Val Ala Asp
Arg Val Asp Ala
Arg Val Glu Gly
Arg Val Gly Glu
Ser Pro Arg Thr
Ser Pro Thr Arg
Ser Arg Pro Thr
Ser Arg Thr Pro
Ser Thr Pro Arg
Ser Thr Arg Pro
Thr Pro Arg Ser
Thr Pro Ser Arg
Thr Arg Pro Ser
Thr Arg Ser Pro
Thr Ser Pro Arg
Thr Ser Arg Pro
Val Ala Asp Arg
Val Ala Arg Asp
Val Asp Ala Arg
Val Asp Arg Ala
Val Glu Gly Arg
Val Glu Arg Gly
Val Gly Glu Arg
Val Gly Arg Glu
Val Gly Val Trp
Val Gly Trp Val
Val Arg Ala Asp
Val Arg Asp Ala
Val Arg Glu Gly
Val Arg Gly Glu
Val Val Gly Trp
Val Val Trp Gly
Val Trp Gly Val
Val Trp Val Gly
Trp Ala Ala Ile
Trp Ala Ala Leu
Trp Ala Ile Ala
Trp Ala Leu Ala
Trp Gly Val Val
Trp Ile Ala Ala
Trp Leu Ala Ala
Trp Val Gly Val
Trp Val Val Gly
octyl-2-acetamido-3,4,6-tri-o-acetyl-2-deoxy-beta-d-glucopyranoside
[1-[(2-methylpropan-2-yl)oxycarbonyl]-5-[[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]amino]indol-2-yl]boronic acid
1H-Indole-1-carboxylic acid, 2-borono-5-[[4-[(1,1-dimethylethoxy)carbonyl]-1-piperazinyl]methyl]-, 1-(1,1-dimethylethyl) ester
2-[(2S,3S)-1-[tert-butyl(dimethyl)silyl]-3-[(1R)-1-[tert-butyl(dimethyl)silyl]oxyethyl]-4-oxoazetidin-2-yl]-2-methylpropanedioic acid
Erk5-IN-1
ERK5-IN-1 is a potent ERK5 inhibitor with an IC50 of 87±7 nM. ERK5-IN-1 also inhibits LRRK2[G2019S] with an IC50 of 26 nM.
4-{4-[2-(1A,7A-Dimethyl-4-oxy-octahydro-1-oxa-4-aza-cyclopropa[A]naphthalen-4-YL)-acetylamino]-phenylcarbamoyl}-butyric acid
Trifarotene
D - Dermatologicals > D10 - Anti-acne preparations > D10A - Anti-acne preparations for topical use > D10AD - Retinoids for topical use in acne C274 - Antineoplastic Agent > C2122 - Cell Differentiating Agent > C1934 - Differentiation Inducer C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C804 - Retinoic Acid Agent C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids D003879 - Dermatologic Agents
Tert-butyl 4-[(4-amino-3-quinolin-3-ylpyrazolo[3,4-d]pyrimidin-1-yl)methyl]piperidine-1-carboxylate
Panax ginseng Tetrapeptide
Constituent of Panax ginseng (ginseng). Panax ginseng Tetrapeptide is found in tea.
(2S)-N-[(4S,4aR,6S,8S,8aR)-6-(hydroxymethyl)-8-methoxy-7,7-dimethyl-4a,6,8,8a-tetrahydro-4H-pyrano[3,2-d][1,3]dioxin-4-yl]-2-hydroxy-2-[(2R,5R,6R)-2-methoxy-5,6-dimethyl-4-methylideneoxan-2-yl]acetamide
N-[[(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid phenyl ester
N-[[(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid phenyl ester
N-[[(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid phenyl ester
1-(3,5-dimethyl-4-isoxazolyl)-3-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]urea
N-[[(8S,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid phenyl ester
N-[[(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid phenyl ester
N-[[(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid phenyl ester
N-[[(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid phenyl ester
(8R,9R,10R)-9-[4-(2-cyclopropylethynyl)phenyl]-10-(hydroxymethyl)-N-(2-methoxyphenyl)-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
N-[[(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid phenyl ester
N-[[(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid phenyl ester
1-(3,5-dimethyl-4-isoxazolyl)-3-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-[(2S,3R,6S)-6-[2-[4-(1-hydroxycyclopentyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-methoxyphenyl)urea
1-[(2S,3S,6S)-6-[2-[4-(1-hydroxycyclopentyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-methoxyphenyl)urea
N-[[(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid phenyl ester
N-[[(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid phenyl ester
1-(3,5-dimethyl-4-isoxazolyl)-3-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3,5-dimethyl-1,2-oxazol-4-yl)-3-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3,5-dimethyl-4-isoxazolyl)-3-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-(3,5-dimethyl-1,2-oxazol-4-yl)-3-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-[(2R,3R,6R)-6-[2-[4-(1-hydroxycyclopentyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-methoxyphenyl)urea
1-[(2S,3S,6R)-6-[2-[4-(1-hydroxycyclopentyl)triazol-1-yl]ethyl]-2-(hydroxymethyl)oxan-3-yl]-3-(2-methoxyphenyl)urea
1-(3,5-dimethyl-4-isoxazolyl)-3-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-[(2S,3R,6R)-6-[2-[4-(1-hydroxycyclopentyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-methoxyphenyl)urea
1-(3,5-dimethyl-4-isoxazolyl)-3-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]urea
1-(3,5-dimethyl-4-isoxazolyl)-3-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]urea
1-(3,5-dimethyl-4-isoxazolyl)-3-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]urea
1-(3,5-dimethyl-4-isoxazolyl)-3-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-[(2R,3S,6R)-6-[2-[4-(1-hydroxycyclopentyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-methoxyphenyl)urea
1-[(2R,3S,6S)-6-[2-[4-(1-hydroxycyclopentyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-methoxyphenyl)urea
1-[(2R,3R,6S)-6-[2-[4-(1-hydroxycyclopentyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-methoxyphenyl)urea
Mutant IDH1-IN-2
Mutant IDH1-IN-2 is a inhibitor of mutant Isocitrate dehydrogenase (IDH) proteins, with IC50 of in LS-MS biochemical assay, IC50 of 16.6 nM in Fluorescence biochemical assay. Target: Mutant IDH1 Mutant IDH1-IN-2 has a neomorphic activity and in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer. More bioactivity information in Patent WO 2013046136A1 (Example 224).